Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Investments
Developing a bacteriophage platform technology for use in animal health has taken Polish company Proteon Pharmaceuticals a decade to master. Chief operating officer Mathew Tebeau talks to Animal Pharm analyst Malcolm Flanagan about the firm's past and future.
Swedish firm Oasmia Pharmaceuticals is aiming to list its veterinary assets on the Nasdaq through its wholly-owned US subsidiary.
Merck Animal Health has acquired Uruguayan veterinary vaccine specialist Prondil.
One possible path for Elanco next year could see it become a standalone entity. While this option will have some benefits for Elanco, it would see the firm lose the R&D capabilities its parent company has to offer. Animal Pharm editor Joseph Harvey takes a closer look at the potential situation.
Canadian business Avivagen has closed a private placement worth approximately Can$4 million ($3.1 million).
Fledgling Israeli tilapia-breeding specialist AquiNovo has boosted its commercialization prospects with a $1.5 million investment from French animal health company Neovia.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.